Table 4.
Pathogen | SF | BC | Probably contaminant | Pathogen in sputuma |
Therapeutic intervention |
Comment |
---|---|---|---|---|---|---|
C. albicans | + | + | - | + | Fluconazole i.v. | Totally implantable venous access port; sepsis |
C. albicans | + | + | - | + | Fluconazole i.v. | Central venous line; candida culture at top of line positive; sepsis |
S. maltophilia | + | - | - | + | Trimethoprim/sulfamethoxazole i.v. |
Intermittent respiratory tract colonization with S. maltophilia |
P. aeruginosa | + | - | - | + | - | Intermittent respiratory tract colonization with P. aeruginosa; P. aeruginosa antibodies negative; empiric antibiotic treatment covered P. aeruginosa |
P. aeruginosa | + | - | - | + | - | Chronic respiratory tract infection with P. aeruginosa; empiric antibiotic treatment covered P. aeruginosa |
K. pneumoniae | + | - | - | - | - | Empiric antibiotic treatment covered K. pneumonia |
S. aureus | - | + | - | Intermittent | - | Erysipelas, left foot; Empiric treatment covered S. aureus |
E. cloacae | + | - | + | - | - | |
E. cloacae | + | - | + | - | - | |
S. epidermidis | - | + | + | - | - | |
S. epidermidis | - | + | + | - | - |
SF SeptiFast, BC blood culture, C Candida, P Pseudomonas, K Klebsiella, E Enterobacter, S Staphylococcus, i.v intravenous
aPathogen in sputum: pathogen detected in sputum during the previous year